SynthesisThe Cochrane database of systematic reviews2012
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.
Synthesis in The Cochrane database of systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 107 citations in OpenAlex.
- Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.Internal medicine (Tokyo, Japan) · 2020Trial
- Trial
- POEMS syndrome-An unusual cause for high-gradient ascites.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea.Journal of Korean medical science · 2024Article
- Castleman disease variant of POEMS syndrome without M protein: a case report.Frontiers in oncology · 2024Article
- Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.Blood cancer journal · 2023Article
- Case report: POEMS syndrome masquerades as diabetic foot.Frontiers in neurology · 2023Article
- POEMS syndrome presents with a distended abdomen: A case report.The Journal of international medical research · 2023Article
- Castleman disease.Nature reviews. Disease primers · 2021Review
- Two cases of special POEMS syndrome without monoclonal protein expression: a case report and literature review.The Journal of international medical research · 2021Review
- Vascular Dysfunction Induced by Mercury Exposure.International journal of molecular sciences · 2019Review
- POEMS syndrome: clinical update.Journal of neurology · 2019Review
- A case report of POEMS syndrome with renal involvement as immunotactoid glomerulopathy.Medicine · 2018Article
- Advances in the Treatment of Paraproteinemic Neuropathy.Current treatment options in neurology · 2017Review
- Alcohol Misuse Link to POEMS Syndrome in a Patient.Cancers · 2017Article
- POEMS Syndrome: an Enigma.Current hematologic malignancy reports · 2017Review
- Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome.BMJ supportive & palliative care · 2016Article
- Monoclonal gammopathy-associated pure red cell aplasia.British journal of haematology · 2016Article
- Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment.Leukemia · 2016Article
- POEMS syndrome and calciphylaxis: an unrecognized cause of abnormal small vessel calcification.Orphanet journal of rare diseases · 2016Review
Corrections and comments
- Update of
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPOEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome is a rare cause of demyelinating and axonal mixed neuropathy with monoclonal plasma cell proliferative disorder and multiorgan involvement. The pathogenesis of POEMS syndrome is not well understood, but overproduction of vascular endothelial growth factor (VEGF), probably secreted by plasmacytomas, is likely to be responsible for most of the characteristic symptoms. POEMS syndrome is a potentially fatal disease, and patients' quality of life deteriorates because of progressive neuropathy, massive pleural effusion or ascites, or thromboembolic events. There is a need for efficacious therapy to improve prognosis. This is the first update of a review first published in 2008.
objectivesTo assess the effects of treatment for POEMS syndrome. SEARCH
methodsWe searched the Cochrane Neuromuscular Disease Group Specialized Register (23 February 2012), CENTRAL (2012, Issue 2), MEDLINE (January 1966 to February 2012), EMBASE (January 1980 to February 2012) and CINAHL Plus (January 1937 to February 2012) for all papers on POEMS syndrome SELECTION CRITERIA: We sought all randomized and quasi-randomized controlled trials, and non-randomized controlled studies. Since we discovered no such clinical trials, we assessed and summarized all retrospective case series including five or more patients in the 'Discussion' section. DATA COLLECTION AND ANALYSIS: Two review authors independently reviewed and extracted details of all potentially relevant trials with any treatment for POEMS syndrome. We then collated and summarized information on the outcome. MAIN
resultsWe found no randomized or non-randomized prospective controlled trials of treatment for POEMS syndrome. We summarized the results of retrospective case series containing five or more patients in the 'Discussion' section. AUTHORS'
conclusionsThere are no randomized or quasi-randomized controlled clinical trials of treatment for POEMS syndrome on which to base practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.